Compare RYN & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYN | CYTK |
|---|---|---|
| Founded | 1926 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.6B |
| IPO Year | 1994 | 2004 |
| Metric | RYN | CYTK |
|---|---|---|
| Price | $20.46 | $77.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 19 |
| Target Price | $26.00 | ★ $89.26 |
| AVG Volume (30 Days) | 1.9M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.73% | N/A |
| EPS Growth | ★ 26.78 | N/A |
| EPS | ★ 3.03 | N/A |
| Revenue | ★ $484,485,000.00 | $13,368,000.00 |
| Revenue This Year | $214.97 | $7.37 |
| Revenue Next Year | $10.35 | $310.19 |
| P/E Ratio | $6.78 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.49 | $29.31 |
| 52 Week High | $27.34 | $80.20 |
| Indicator | RYN | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 41.96 | 69.50 |
| Support Level | $19.49 | $58.59 |
| Resistance Level | $21.68 | N/A |
| Average True Range (ATR) | 0.48 | 3.62 |
| MACD | -0.08 | 1.39 |
| Stochastic Oscillator | 11.62 | 84.90 |
Rayonier Inc is a timberland real estate investment trust engaged in the ownership, management, and investment of timberlands. The company operates through Southern Timber, Pacific Northwest Timber, and Real Estate segments. The Southern Timber and Pacific Northwest Timber segments are involved in harvesting timber and related activities, as well as value-added services such as licensing properties for hunting, leasing land for mineral extraction and communication infrastructure, land-based solutions including carbon capture and solar energy, and log trading. The Real Estate segment is engaged in land sales across various categories, as well as residential and commercial leasing activities. It generates the majority of its revenue from the Southern Timber segment.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.